Back to Search
Start Over
[New European approvals: Carfilzomib with daratumumab and dexamethasone in refractory or relapsed multiple myeloma after a first line of treatment].
- Source :
-
Bulletin du cancer [Bull Cancer] 2021 Jun; Vol. 108 (6), pp. 563-565. Date of Electronic Publication: 2021 May 19. - Publication Year :
- 2021
- Subjects :
- Antibodies, Monoclonal therapeutic use
Bortezomib therapeutic use
Clinical Trials, Phase III as Topic
Dexamethasone therapeutic use
Drug Administration Schedule
Drug Approval
Europe
Humans
Lenalidomide therapeutic use
Multicenter Studies as Topic
Oligopeptides therapeutic use
Randomized Controlled Trials as Topic
Antineoplastic Agents therapeutic use
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Drug Resistance, Neoplasm
Multiple Myeloma drug therapy
Neoplasm Recurrence, Local drug therapy
Subjects
Details
- Language :
- French
- ISSN :
- 1769-6917
- Volume :
- 108
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Bulletin du cancer
- Publication Type :
- Periodical
- Accession number :
- 34020786
- Full Text :
- https://doi.org/10.1016/j.bulcan.2021.04.005